BRAIN Biotech AG (HAM:BNN) ROCE %: -17.24% (As of Mar. 2026)

What is BRAIN Biotech AG ROCE %?

BRAIN Biotech AG HAM:BNN 66 ROCE % is -17.24% as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 66/100 and a GF Value™ of €2.52 (Modestly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BRAIN Biotech AG's annualized ROCE % for the quarter that ended in Mar. 2026 was -17.24%.

BRAIN Biotech AG (HAM:BNN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BRAIN Biotech AG ROCE % Related Terms

BRAIN Biotech AG ROCE % Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG ROCE % Chart

BRAIN Biotech AG Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

ROCE %

Get a 7-Day Free Trial

-5.95

-9.16

-12.05

-15.45

-17.46

BRAIN Biotech AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-12.53	5.05	-43.59	-13.01	-17.24

66GF Score

BRAIN Biotech AG HAM:BNN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

BRAIN Biotech AG ROCE % Calculation

BRAIN Biotech AG's annualized ROCE % for the fiscal year that ended in Sep. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2025 )		(A: Sep. 2024 )		(A: Sep. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2025 )		(A: Sep. 2024 )		(A: Sep. 2025 )
	=	-9.818	/	( ( (88.737 - 25.006)	+	(66.337 - 17.6) )	/ 2 )
	=	-9.818	/	( (63.731	+	48.737)	/ 2 )
	=	-9.818	/	56.234
	=	-17.46 %

BRAIN Biotech AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-8.284	/	( ( (66.905 - 17.68)	+	(62.657 - 15.76) )	/ 2 )
	=	-8.284	/	( ( 49.225	+	46.897 )	/ 2 )
	=	-8.284	/	48.061
	=	-17.24 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -17.24% mean?

BRAIN Biotech AG (HAM:BNN) has a ROCE % of -17.24% as of Mar. 2026.

Is BRAIN Biotech AG's ROCE % too high?

BRAIN Biotech AG's current ROCE % is -17.24%. Overall, BRAIN Biotech AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does BRAIN Biotech AG's ROCE % compare to LIN and SHW?

BRAIN Biotech AG's ROCE % of -17.24% can be compared against companies in the Chemicals industry. The industry median ROCE % is 6.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Chemicals company?

The median ROCE % among Chemicals companies is 6.42, based on 1,595 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median ROCE % is 6.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BRAIN Biotech AG's current ROCE % is -17.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is BRAIN Biotech AG stock overvalued right now?

Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.52, compared to a current price of €2.82 — trading 11.9% above its estimated fair value. The current ROCE % is -17.24%. BRAIN Biotech AG's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current ROCE % is -17.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.82 is trading 11.9% above its estimated GF Value™ of €2.52. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

ROCE %: -17.24%
GF Value™: €2.52 vs. price of €2.82 (11.9% above fair value)
GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRAIN Biotech AG Business Description

Industry Basic Materials Chemicals

Comparable Companies XTER:NTG XTER:MZX XTER:2HRA XTER:UZU LIN XPAR:AI SHW ECL APD XSWX:GIVN SHSE:600309 XSWX:SIKA SZSE:002466 OCSE:NSIS B SHSE:603256 BOM:500820 PPG TPE:1303 XSGO:SQM-B LYB

Other Exchanges 0RFI:UK BNN:Germany

Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website https://www.brain-biotech.com

BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.

66GF Score

Get the complete analysis for HAM:BNN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.82

Price

€2.52

GF Value

View HAM:BNN Analysis

See ROCE % data for all stocks →